CASE REPORT

Acute vision loss in Guillain–Barré syndrome: A case series and review of literature

Abhay Ranjan1*, Ramdas Pandurangrao Solanke1, Neetu Sinha2 and Vidya Bhushan3

Abstract

Background: Acute vision loss in Guillain–Barré syndrome is rarely reported in literature. No case of vision loss in Guillain–Barré syndrome due to Angle closure glaucoma has been reported in AIDP variant GBS.

Case presentation: We report three patients with an acute inflammatory demyelinating polyradiculoneuropathy subtype of GBS who developed acute vision loss during the course of disease. Two patients had autonomic dysfunction with hypertension, in which one patient presented with painful acute vision loss and was diagnosed with Angle closure glaucoma and another patient had painless vision loss which was due to posterior reversible encephalopathy syndrome. Third patient presented with bilateral papilledema with raised cerebrospinal fluid protein and intracranial pressure. Vision in all the three patients improved after treatment.

Conclusion: Patient with GBS, with autonomic dysfunction and hypertension or elevated cerebrospinal fluid protein may present with acute vision loss during the course of the disease. Early diagnosis and management help to improve vision and prevent permanent vision loss in these patients.

Keywords: Guillain–Barré syndrome, Acute inflammatory demyelinating polyradiculoneuropathy, Angle closure glaucoma, Posterior reversible encephalopathy syndrome, Papilledema, Vision loss

Introduction

Guillain–Barre syndrome (GBS), an inflammatory disease of the peripheral nervous system, is rapidly progressive flaccid symmetrical weakness of upper and lower limbs with or without sensory or autonomic disturbances having a monophasic course of less than 4 weeks. GBS is the most common cause of acute flaccid paraplegia with annual global incidence of approximately 1–2 per 100,000 person-year [1]. In India, acute inflammatory demyelinating polyradiculoneuropathy (AIDP) is the most common electrophysiological subtype of GBS, occurring in approximately three quarters of patients [2]. Patients with GBS typically present with weakness and sensory signs in the legs that progress to the arms and cranial muscles, although the clinical presentation of the disease is heterogeneous and several distinct clinical variants exist [3]. Acute vision loss in GBS is rarely reported in the literature. We report three cases of GBS who had acute bilateral vision loss during their course of illness.

Case presentation

Case # 1

A 44-year-old female presented to our outpatient department (OPD) with progressive weakness in all limbs for 4 days. Patient was hypertensive and had undergone laparoscopic cholecystectomy 10 days prior to onset of symptoms. On clinical examination, she had areflexic quadreperesis and Medical Research Council (MRC) sum score was 23/60. Nerve conduction study (NCS machine model-Model-Key Point, manufactured by Medtronic, Denmark, year of manufacture—2005) findings were suggestive of acute inflammatory demyelinating polyradiculoneuropathy subtype of GBS. Cerebrospinal fluid (CSF) analysis showed albuminocytological dissociations [CSF protein 156.6 mg/dl; cells:...
5 (all lymphocytes), glucose: 61 mg/dl (blood glucose: 96 mg/dl)). Within 4 days of admission, she developed breathing difficulty and was put on mechanical ventilation. She had autonomic dysfunction, accompanied by severe tachycardia (156 beats/min) which was controlled by metoprolol, and her pupils were equal on both sides and reacting to light. She was administered Intravenous Immunoglobulin (IV Ig) and gradually weaned off from ventilator after 2 weeks. Her MRC sum score improved to 42/60. Two days later, she was weaned off ventilator; at night she had acute binocular diminished vision along with pain. At the time of onset of diminished vision, she could perceive hand movement and projection of light in both eyes, her pupils were mildly dilated and sluggishly reacting to light. The vision further deteriorated the next morning, the movement of the hand could be felt in the left eye but she could not perceive projection of light in the right eye. Direct and indirect pupillary reflexes were absent. A direct ophthalmoscope (Model: Beta 200 (2.5 V XHL); manufactured by Heine, Germany; year of manufacture: 2012.) examination of the fundus revealed bilateral corneal oedema and shallow anterior chamber (right > left). On her tonometry, intraocular pressure was raised (right eye: 31 mm of Hg and left eye: 27 mm of Hg). Slit lamp (Model: SL CAM–ICM7; manufactured by Appasamy Associates India; year of manufacture: 2018.) examination of both eyes showed mild corneal edema, shallow anterior chamber, and mid dilated irregular fixed pupil more on the left eye than right eye (Fig. 1). On the anterior segment optical coherence tomography (AS-OCT) [Model: DRI OCT Triton, manufactured by Topcon corporation, Tokyo, Japan. Year of manufacture: 2015], the angle of anterior chamber appeared narrow (less than 20°) (Fig. 2). Extraocular movements were normal. MRI (Model: Optima MR 360, manufactured by General Electric Company, country: Wisconsin, USA, year of manufacture: August 2016) of the brain with orbits showed bilateral tortuous optic nerves and dilated perioptic subarachnoid spaces. She was diagnosed to have bilateral angle-closure glaucoma (ACG) and was treated with intravenous mannitol and oral acetazolamide. After 3 days of treatment, the vision...

Fig. 1 Slit lamp image: A Before the treatment in Rt eye, mild corneal edema, shallow anterior chamber, mid dilated irregular fixed pupil with picking at 8 and 12 O’clock position was observed. B After the treatment, the cornea is clear, the pupils are smaller than before the treatment, the response to light is slow, and the sphincter is atrophy at 12–2 o’clock position. Right eye after treatment revealed clear cornea, constricted pupil than before treatment and sluggish reaction to light, sphincter atrophy 12–2 o’clock position. C Left eye before treatment demonstrates. Severe diffuse corneal edema with shallow anterior chamber, irregular pupil and posterior synechiae from 2 to 6 O’clock position. D Left eye after treatment showed improvement in corneal edema
in the left eye improved to a finger count at 3 feet, but the right eye could only perceive hand movement. On slit light examination, corneal edema decreased in both eyes. The patient underwent a trabeculectomy in the right eye for non-improvement, and his vision improved to a finger count at 2 feet. After 2 months her vision was 6/18 in right eye and 6/12 in left eye.

**Case # 2**
A 22-year-old lady presented to our OPD with a history of progressive weakness of both upper and lower limbs for 20 days. She was diagnosed as a case of GBS and was given IV Ig. The patient’s weakness was improved and she was able to walk with slight support. Three days after IV Ig, she again developed progressive weakness in all her limbs, accompanied by mild to moderate persistent holocranial headache and decreased binocular vision. On examination, MRC sum score was 30/60 with hypotonia and generalized areflexia. Nerve conduction studies showed findings of AIDP variant GBS. CSF study revealed albuminocytological dissociations (CSF: Protein 389.6 mg/dl, cells 5 (all lymphocytes), glucose: 86 mg/dl (blood glucose: 105 mg/dl)) with markedly raised protein (389.6 mg/dl) and CSF opening pressure was 280 mm of CSF. In the ophthalmological evaluation, her vision in both eyes was 6/18, and her extraocular movements were normal. On fundoscopy she had grade IV papilledema in both the eyes (Fig. 3). MRI of brain and orbit revealed...
distension of perioptic nerve sheath, vertical tortuosity and flattening of posterior sclera (Fig. 4). Patient was given IV Ig and oral acetazolamide. After 1 month of treatment her vision improved from 6/18 to 6/6 and MRC sum score improved to 50/60.

Case # 3
A 40-year-old gentle man presented with complains of progressive weakness, tingling and paraesthesia of all limbs since past 7 days. MRC sum score of limbs was 28/60. He had bilateral facial and bulbar weakness. He was intubated and put on mechanical ventilation. He had dysautonomia with tachypnea, tachycardia and hypertension. Nerve conduction studies were suggestive of AIDP variant GBS. The CSF study showed albuminocytological dissociation [Protein 167 mg/dl, cells < 5 (all lymphocytes), glucose: 78 mg/dl (blood glucose: 102 mg/dl)]. He was given IV Ig and extubated within 3 days. After 5 days of IV Ig treatment, he developed acute onset bilateral painless vision loss. On ophthalmic examination perception of light was absent in both eyes but pupils were reacting to light. Blood pressure in supine posture was 150/100 mm of mercury with no significant postural drop (she had blood pressure of 100/60 mm of Hg prior to illness). Magnetic resonance imaging (MRI) of brain revealed increased signal on T2W and FLAIR images in white matter of bilateral parieto-occipito-temporal region with patchy hyperintense signal on diffusion weighted image (DWI) (Fig. 5). He was diagnosed with posterior reversible encephalopathy syndrome (PRES) and was managed conservatively. After 7 days, he was able to count his finger at a distance of 6 m. After 6 months, his binocular vision was 6/6. Power of limbs improved to MRC sum score of 44/60.

Discussion
Guillain–Bare syndrome is an immune mediated disorder of peripheral nervous system in which autonomic dysfunction is seen in up to two-thirds of patients in GBS which includes blood pressure fluctuations, arrhythmias, vasomotor dysfunction, and gastrointestinal (GI) motility dysregulation [3]. Few case reports associate autonomic dysfunction with GBS and acute bilateral vision loss such as posterior reversible encephalopathy syndrome (PRES) and angle closure glaucoma. There are also case reports of acute vision loss and papilledema in GBS.

There are few case reports of acute angle-closure glaucoma in Miller fisher Variant of GBS reported in literature. ACG is a common form of glaucoma in which the anterior chamber of eyeball is closed, and the aqueous drainage of the eye is blocked. First case of unilateral ACG with diminished visual acuity in GBS (Miller Fisher variant) was reported in 2006 [4]. A case of MFS variant GBS with bilateral simultaneous ACG was described in a 55-year-old person who presented with bilateral blurred vision and unsteadiness [5]. Won Yeol Ryu, and colleagues reported a case of MFS without autonomic dysfunction who presented with right eye pain and blurred vision and was diagnosed as a case of acute ACG [6]. Blurred vision and eye pain can be a presenting complaint in MFS variant GBS associated ACG [7]. As far as we know, this is the first case of GBS AIDP variant with autonomic dysfunction due to ACG-induced vision loss on both sides (Table 1). The pathophysiology attributed
to ACG in MFS is due to oculomotor autonomic neuropathy leading to pupillary dilatation and narrowing or blockade of anterior chamber of eye [4, 5, 7]. Autonomic dysfunction can prolong in GBS and should be monitored even during subacute phase [8]. In our case ACG occurred 2 weeks after onset of illness with autonomic dysfunction still persisting and on ophthalmologic examination there was decrease in the angle of anterior chamber of both eyes, which might be due to oculomotor autonomic neuropathy, that led to increase in intraocular pressure.

**Table 1** Summary of cases reported in literature of vision loss in GBS due to Angle closure glaucoma

| Variant of GBS | Baxter JM et al. [5] | Han J et al. [7] | Ryu, W. Y. et al. [6] | Brittain CJ et al. [4] | Our case |
|----------------|----------------------|------------------|-----------------------|------------------------|----------|
| Age (years)/sex| MFS 55/male          | MFS 78/female    | MFS 75/male           | MFS 64/female          | AIDP 45/female |
| Onset of vision loss | Presenting complaint | Presenting complaint | Presenting complaint | Presenting complaints | Present |
| IOP at onset (RE and LE) | 56 mm of Hg | 48 mm of Hg | Unilateral (left eye) | Unilateral (Right Eye) | Bilateral |
| BCVA at onset (RE and LE) | HM 6/18 | 0.6 PL | 6/9 | RE-HM | LE-6/60 |
| ACD | Absent | Present | Present | Not Mentioned | Present |
| CSF Proteins | Acetazolamide | Mannitol | Mannitol | Topical Latanaprost | Acetazolamide |
| Medical treatment | Topical pilocarpine, timolol and ipidine | Topical pilocarpine | Topical Timolol and Timolol | Topical Timolol, Latanaprost, lopidine | Topical timolol |
| Surgical treatment | Laser peripheral iridotomy | None | Laser peripheral iridotomy | Laser peripheral iridotomy | Laser peripheral iridotomy |
| IVIg therapy | Given | Given | Given | Given | Given |
| IOP after treatment (RE and LE) | 23 mm of Hg | 18 mm of Hg | 11 mm of Hg | 13 mm of Hg | 19 mm of Hg |
| Time of reassessment after starting of treatment | 6 months | 2 days | 2 days | 2 months | 2 months |
| BCVA after treatment (RE and LE) | RE-6/6 | RE-0.8 | RE-10/20 | RE-6/6 | RE-6/18 |

**Notes:**

- MFS: Miller Fisher variant, AIDP: acute inflammatory demyelinating polyradiculoneuropathy, mm of Hg: millimetre of mercury, BCVA: best corrected visual acuity, CSF: cerebrospinal fluid, IVIg: intravenous immunoglobulins, RE: right eye, LE: left eye, ACD: albumin cytological dissociation, IOP: intraocular pressure, HM: hand movement, PL: perception of light, RE: right eye, LE: left eye

![Fig. 5 A] Axial FLAIR MRI image of brain demonstrates symmetrical hyperintense signal in white matter of bilateral parieto-occipital region with some cortical involvement (Red arrows). B, C: Axial DWI and ADC image of brain demonstrates hyperintense signal in right occipito-temporal region (red arrows) with no corresponding decrease in ADC signal.
pressure and cornea oedema, which improved on follow up examination after managing ACG.

In previous literature, papilledema and its association with elevated CSF protein have been reported as a rare complication of GBS. A case of definite papilledema in GBS was first reported by Gilpin and colleagues [9]. In 1966 Morley JB and colleagues, reported a number of case reports and a case series describing papilledema and decreased vision in GBS [10]. Morley and colleagues reported 4 cases of GBS and papilledema who presented with headache and sensory-motor weakness of limbs. Most of the cases that are reported in literature, papilledema in GBS usually presents with headache and/or diplopia and vision loss as a presentation is rare. Similar to our case, the literature describes the recurrence of GBS symptoms with decreased vision, headache, and bilateral papilledema after completing the first dose of IV Ig, which was managed by repeated IV Ig, intravenous mannitol and oral acetazolamide treatment [11]. Kharbanda P S and colleagues, Mathis S and colleagues, Gross FJ and colleagues. (in human immunodeficiency virus infection) and Hui-Jun Wen also reported decreased vision and increased intracranial pressure due to papilledema in GBS [12–15] (Table 2). The pathophysiology behind papilledema and headache is cerebral oedema caused by elevated CSF protein, and autopsy reveals swelling of nerve cells [16]. Similarly, in our case, there was increase in cerebrospinal fluid protein with increase in intracranial pressure, resulting in severe papilledema on both sides. IV Ig itself may cause aseptic meningitis, which may mimic pseudotumor cerebri (raised intracranial pressure) but in addition there is photophobia, fever, chills, positive Kernig's and Brudzinski's signs along with CSF showing an increased level of nucleated cells, high protein content and negative culture results [17]. In our case there was no fever or sign of meningeal irritation and CSF did not show raised cells and blurring of vision was present.

PRES in GBS with acute vision loss is a rare complication of GBS reported in literature. PRES is a

| Table 2 Summary of cases reported in literature of GBS with vision loss due to Papilledema |
|---|
| Variant of GBS | Christina Doxaki et al. [11] | Kharbanda PS et al. [12] | Mathis S et al. [13] | Gross FJ et al. [14] | Hui-Jun Wen [15] | Our case |
| Age (year)/ sex | AIDP | AIDP | AIDP | AIDP | AIDP | AIDP |
| Visual symptoms | 12/Female | 35/Female | 42/Male | 27/Female | 43/f | 25/Female |
| Visual symptoms | Diminished vision | Diminished vision | Diminished vision | Transient visual obscuration | Diminished vision |
| Headache | Present | Present | Absent | Not mentioned | Absent | Present |
| Signs of dysautonomia | Present | Present | Absent | Not mentioned | Absent | Present |
| BCVA (RE and LE) | Reduced | PL | Reduced | Reduced | RE-20/20 | RE-20/30 | RE-6/60 |
| Papilledema | Present | Present | Present | Present | Normal | Present |
| Signs of raised ICP on Neuroimaging | Not mentioned | Not mentioned | Not mentioned | Not mentioned | Normal | Present |
| CSF opening pressure | 460 mm of CSF | 420 mm of CSF | 150 mm of CSF | 310 mm of CSF | Not Mentioned | 280 mm of CSF |
| ACD (CSF Proteins) | Present | Reduced | Present (435 mg/dl) | Present (325 mg/dl) | Present (862 mg/l) | Present (78 mg/dl) |
| IVIG therapy | Given | Given | Given | – | Given | Given |
| Other treatment given | Acetazolamide | Acetazolamide | Acetazolamide | Intravenous Dexamethasone and Mecobalamin | Mannitol Acetazolamide Corticosteroid |
| Reassessment of vision after treatment | After 2 months | After 1 year | After ~ 6 months | 3 weeks | After 1 month |
| BCVA after treatment | RE-6/6 LE-6/6 | Not mentioned | RE-6/6 LE-6/6 | RE-20/20 LE-20/20 | Blind spot normal sized | RE-6/6 LE-6/6 |

GBS Guillain–Barré syndrome, AIDP acute inflammatory demyelinating polyradiculoneuropathy, PL projection of light, mm millimetre, BCVA best corrected visual acuity, CSF cerebrospinal fluid, IV Ig intravenous immunoglobulin, RE right eye, LE left eye, ACD albumin cytological dissociation, ICP intracranial pressure, RE right eye, LE left.
clinicroadiological syndrome defined by the presence of headache, altered mentation, seizures, visual dysfunction and focal neurological deficits [18]. PRES in GBS may occur due to disease itself or its treatment (IV Ig) or it can precede the onset of GBS in few cases [19, 20]. In a review article on GBS and PRES, 13 such cases were described. In the review, about 92% of patients were female with average age of 63 years, 70% of patients had GBS symptoms prior to PRES, all the patient were hypertensive at the time of presentation, and most of the patient were managed with IV Ig [21]. Similarly, our patient had symptoms of GBS before PRES, had autonomic dysfunction and hypertension at the time of presentation, and received IV Ig. Regardless of the review, our patient was male and of younger age (40 years vs 63 years). Most of the PRES cases in GBS reported in the literature, presented with headache, epilepsy, and/or encephalopathy. Reports of vision loss in PRES and GBS are rare [21–24] (Table 3). A case of GBS with PRES was recently reported, in which the symptoms of headache and decreased vision (PRES) preceded the symptoms of GBS before [19, 20]. Most widely accepted theory behind pathophysiology of PRES is breakdown of cerebral autoregulation due to a rapid rise in blood pressure leading to disruption of the blood–brain barrier. The exact mechanism of PRES in GBS is still unknown but the proposed mechanism for PRES in GBS include autonomic dysfunction and impaired cerebral autoregulation due to increase in blood pressure leading to raised cerebral blood flow and vasogenic oedema [26]. In our case also she had a blood pressure of 100/60 mm of Hg in supine posture prior to the illness. During the course of illness due to dysautonomia there was a sudden rise in blood pressure to 150/100 mm of Hg leading to failure of cerebral autoregulation, resulting in PRES. In literature, PRES in MFS without autonomic dysfunction have been reported as a complication of IV Ig associated with or without hypertension [27, 28]. However, in our case, autonomic dysfunction was present prior to start of IV Ig treatment, but additional effect of IV Ig on increased blood pressure could not be ruled out.

**Conclusions**

In patient of GBS with autonomic dysfunction and hypertension with bilateral diminished vision, the possibility of angle closure glaucoma should be considered if it is associated with eye pain. In a GBS patient with autonomic dysfunction, hypertension and bilateral vision loss, if accompanied by eye pain, the possibility of angle-closure glaucoma should be considered. And if it is not associated with eye pain, the possibility of PRES should be considered. In GBS without autonomic dysfunction, but with decrease vision and raised CSF protein, the possibility of increased intracranial pressure and papilledema should be strongly considered. Prompt diagnosis and management help in complete or near complete improvement in vision and prevents permanent vision loss.

**Abbreviations**

GBS: Guillain–Barré syndrome, AIDP: Acute inflammatory demyelinating polyradiculoneuropathy, AMAN: acute motor axonal polyneuropathy, IE: intravenous immunoglobulin, PL: projection of light, HM: hand movement, mm: millimetre, Hg: mercury, mg: milligram, dl: decilitre, BCVA: best corrected visual acuity, CSF: cerebrospinal fluid, IV Ig: intravenous immunoglobulin, RE: right eye, LE: left eye, ACD: albuminocytological dissociation

**Table 3** Summary of cases reported in literature of GBS with vision loss due to PRES

| Variant of GBS | Ramakrishnan et al. [23] | Chen A et al. [21] | Nabi S et al. [24] | Joshi S et al. [22] | Our case |
|----------------|--------------------------|-------------------|-------------------|-------------------|---------|
| Age(year)/sex  | AIDP 12/Female            | AMAN 63/Female    | Not Mentioned     | AIDP 40/Male      |
| BCVA (RE and LE)| RE–PL Present            | Reduced           | HM Present 6/36   | 6/18 bilaterally  |
| Other features of dysautonomia | Hypertension (140/90 mm of Hg) | Hypertension (172/98 mm of Hg) | Hypertension (160/100 mm of Hg) | Hypertension (210/100 mm of Hg) |
| Seizure        | Present                   | Present           | Present           | Absent            |
| Neuroimaging showing PRES | Present (not mentioned)  | Present (59 mg/dl) | Present (63 mg/dl) | Present (167 mg/dl) |
| ACD (CSF Protein)| Present (59 mg/dl)       | Present (63 mg/dl) | Present (67 mg/dl) | Present (167 mg/dl) |
| Therapy        | IV Ig Given               | Given             | Given             | Given             |
| Reassess ment done | After 1 month           | After 10 months  | 6 weeks           | 3 months          |
| BCVA at reassessment (RE and LE) | RE-6/6                   | RE-6/6            | RE-6/6            | RE-6/6            |

**Note**

BCVA: best corrected visual acuity, IV Ig: intravenous immunoglobulin, RE: right eye, LE: left eye, AIDP: acute inflammatory demyelinating polyradiculoneuropathy, AMAN: acute motor axonal polyneuropathy, IE: intravenous immunoglobulin, PL: projection of light, HM: hand movement, mm: millimetre, Hg: mercury, mg: milligram, dl: decilitre, BCVA: best corrected visual acuity, CSF: cerebrospinal fluid, IV Ig: intravenous immunoglobulin, RE: right eye, LE: left eye, ACD: albuminocytological dissociation.
Acknowledgements
None.

Authors’ contributions
AF: concept, interpretation, writing and editing of manuscript; RPS: data collection, writing of manuscript; NS: data collection, interpretation of radiological data and editing of manuscript; VB: data collection and interpretation of ophthalmological data. All authors read and approved the final manuscript.

Funding
The authors declare that no financial support has been taken to conduct the research and/or preparation of the article.

Availability of data and materials
All data is provided in full in the results section of this paper.

Declarations

Ethics approval and consent to participate
Informed written consent of participants/their parent taken.

Consent for publication
Written informed consent to publish this information was obtained from study participant.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Neurology, Indira Gandhi Institute of Medical Sciences, Sheikhpura, Patna, Bihar 800014, India. 2Department of Radiology, Indira Gandhi Institute of Medical Sciences, Patna, Bihar, India. 3Regional Institute of Ophthalmology, Indira Gandhi Institute of Medical Sciences, Patna, Bihar, India.

Received: 4 October 2021   Accepted: 13 February 2022
Published online: 07 March 2022

References
1. Sejvar JJ, Baughman AL, Wise M, Morgan OW. Population incidence of Guillain–Barre syndrome: a systematic review and meta-analysis. Neuroepidemiology. 2011;36(2):123–33.
2. Kalita J, Misra UK, Goyal G, Das M. Guillain–Barre syndrome: subtypes and predictors of outcome from India. J Peripher Nerv Syst. 2014;19(1):36–43.
3. Leonard SE, Mandarakas MR, Gondim FFA, Bateman K, Ferreira MLB, Cornblath DR, et al. Diagnosis and management of Guillain–Barre syndrome in ten steps. Nat Rev Neurol. 2019;15(11):671–83.
4. Brittain CJ, Lake D. Acute angle closure in Miller Fisher syndrome. Eye (Lond). 2006;20:739–40.
5. Baxter JM, Alexander P, Maharajan VS. Bilateral, acute angle-closure glaucoma associated with Guillain–Barre syndrome variant. BMJ Case Rep. 2010;21(2010):bcr1120092487.
6. Ryu WY, Kim JK, Jin SW, Shim DH. Acute angle-closure glaucoma in a patient with miller fisher syndrome without pupillary dysfunction. J Glaucoma. 2015;24(2):e5–6.
7. Han J, Ji Y, Cao D, Kang Z, Zhu J. Miller Fisher syndrome with acute angle-closure glaucoma as the first manifestation: a case report. Medicine (Baltimore). 2017;96(50): e9201.
8. Rawat N, Khanna M, Rukmani R, Haldar P. Autonomic dysfunction in patients with Guillain–Barre syndrome in sub-acute phase. J Clin Diagn Res. 2019;13(6):LC16–20.
9. Gilpin S, Moersch FP, Kernohan JW. Polineuropatia: a clinical and pathologic study of a special group of cases frequently referred to as instances of neuritis. Arch Neurol. 1936;55(5):937–63.
10. Morley JB, Reynolds EH. Papilloedema and the Landry-Guillain–Barre syndrome. Case reports and a review. Brain. 1966;89(2):205–22.
11. Doxaki C, Papadopoulou E, Maniadaki I, Tsakalis NG, Palikaras K, Vorgia P. Case report: intracranial hypertension secondary to Guillain–Barre syndrome. Front Pediatr. 2021;8:608695.
12. Kharbanda PS, Prabhakar S, Lal V, Das CP. Visual loss with papilledema in Guillain–Barre syndrome. Neurol India. 2002;50(4):528–9.
13. Mathis S, Le Masson G, Soulages J, Duval F, Soké G, Boissonnot M, et al. Papilloedema and peripheral neuropathies. Neurologist. 2019;24(6):185–93.
14. Gross EJ, Mindel JS. Pseudotumor cerebri and Guillain–Barre syndrome associated with human immunodeficiency virus infection. Neurology. 1991;41(11):1845–6.
15. Wen HJ. Acute bilateral vision deficit as the initial symptom in Guillain–Barre syndrome: a case report. Exp Ther Med. 2018;16(3):2712–6.
16. Joynt RJ. Mechanism of production of papilledema in the Guillain–Barre syndrome. Neurology. 1958;8(1):18–12.
17. Jain RS, Kumar S, Aggarwal R, Kookna JC. Acute aseptic meningitis due to intravenous immunoglobulin therapy in Guillain–Barre syndrome. Oxf Med Case Rep. 2014;2014(7):132–4.
18. Fischer M, Schmutzhard E. Posterior reversible encephalopathy syndrome in patients with Gullain-Barré syndrome: is it a complication of Guillain–Barre syndrome or just a coincidence? J Ophthalmic Vis Res. 2010;17:924–6.
19. Elahi A, Kelkar P, St Louis EK. Posterior reversible encephalopathy syndrome as the initial manifestation of Guillain–Barre syndrome. Neurocrit Care. 2004;1:465–8.
20. Chen A, Kim J, Henderson G, Berkowitz A. Posterior reversible encephalopathy syndrome in Guillain–Barre syndrome. J Clin Neurosci. 2015;22(5):914–6.
21. Joshi S, Prentice D, van Heerden J, Chemmanam T. Guillain–Barre syndrome and posterior reversible leukoencephalopathy syndrome: a rare association. BMJ Case Rep. 2020;2020(134): e234184.
22. Ramakrishnan S, Kannan B, Kannan A, Venkatesan EP. Vision loss in Guillain–Barre syndrome: is it a complication of Guillain–Barre syndrome or just a coincidence? J Ophthalmic Vis Res. 2016;11(3):340–1.
23. Nabi S, Rajput HM, Badshah M, Ahmed S. Posterior reversible encephalopathy syndrome (PRES) as a complication of Guillain–Barre’ syndrome (GBS). BMJ Case Rep. 2016;2016: bcr2016216757.
24. Hinchey J, Chaves C, Appignani B, Breen J, Fao L, Wang A, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med. 1996;334(8):494–500.
25. Blackburn D, Chavada G, Dunleavy D, Hoggard N, Sharrack B, Ponnusamy S, et al. Guillain–Barre syndrome (GBS) presenting with posterior reversible encephalopathy syndrome. J Neurol Neurosurg Psychiatry. 2011;82: e6.
26. Nakajima M. Posterior reversible encephalopathy complicating intravenous immunoglobulins in a patient with miller-fisher syndrome. Eur Neurol. 2005;54(1):58–60.
27. Ribeiro BN, Salata TM, Borges RS, Marchiori E. Posterior reversible encephalopathy syndrome following immunoglobulin therapy in a patient with Miller–Fisher syndrome. Radiol Bras. 2016;49(1):58–9.